Effect of apolipoprotein E genotype on Alzheimer's disease neuropathology in a cohort of elderly Norwegians - PubMed (original) (raw)
Clinical Trial
Effect of apolipoprotein E genotype on Alzheimer's disease neuropathology in a cohort of elderly Norwegians
C M Morris et al. Neurosci Lett. 1995.
Abstract
A cohort of elderly Norwegians dying in nursing homes in the Oslo region have been genotyped for the Apolipoprotein E (ApoE) gene. Alzheimer's disease (AD) cortical neuropathology and clinical evidence of dementia were used to assign cases without evidence of other confounding neuropathology. Senile plaque (SP) and neurofibrillary tangle (NFT) densities in frontal, temporal and parietal cortex were then correlated with ApoE genotype to determine any relationship between ApoE genotype and AD pathology. Comparisons with ApoE epsilon 3, epsilon 4 and epsilon 2 allele dosage failed to show any significant effect on cortical SP densities in any cortical area. NFT densities were increased by epsilon 4 allele dosage in the frontal cortex but not in other cortical regions. A reduction was seen in cortical NFT densities with epsilon 2 allele, though again this was not consistently significant in any of the groups. The epsilon 3 allele failed to show any consistent effect on cortical NFT densities. Assessment by individual genotypes showed epsilon 2/3 < epsilon 2/4 < epsilon 3/3 < epsilon 3/4 < epsilon 4/4 which had highest cortical NFT densities in all areas. By genotype, SP densities were generally of the order epsilon 2/4 < epsilon 2/3 < epsilon 3/3 < epsilon 4/4 < epsilon 3/4 though in none of the groups was this significant. Duration of disease showed no consistent effect on neuropathological burden. ApoE genotype may have an effect on determining whether individuals suffer from AD and the age at onset of disease but may only have a minimal effect on pathology burden.
Similar articles
- Apolipoprotein E-epsilon 2 and Alzheimer's disease: genotype influences pathologic phenotype.
Lippa CF, Smith TW, Saunders AM, Hulette C, Pulaski-Salo D, Roses AD. Lippa CF, et al. Neurology. 1997 Feb;48(2):515-9. doi: 10.1212/wnl.48.2.515. Neurology. 1997. PMID: 9040748 - Influence of the apolipoprotein E genotype on amyloid deposition and neurofibrillary tangle formation in Alzheimer's disease.
Nagy Z, Esiri MM, Jobst KA, Johnston C, Litchfield S, Sim E, Smith AD. Nagy Z, et al. Neuroscience. 1995 Dec;69(3):757-61. doi: 10.1016/0306-4522(95)00331-c. Neuroscience. 1995. PMID: 8596645 - Clinicopathologic studies in cognitively healthy aging and Alzheimer's disease: relation of histologic markers to dementia severity, age, sex, and apolipoprotein E genotype.
Berg L, McKeel DW Jr, Miller JP, Storandt M, Rubin EH, Morris JC, Baty J, Coats M, Norton J, Goate AM, Price JL, Gearing M, Mirra SS, Saunders AM. Berg L, et al. Arch Neurol. 1998 Mar;55(3):326-35. doi: 10.1001/archneur.55.3.326. Arch Neurol. 1998. PMID: 9520006 - Apolipoprotein E genotype and cerebral amyloid angiopathy-related hemorrhage.
McCarron MO, Nicoll JA. McCarron MO, et al. Ann N Y Acad Sci. 2000 Apr;903:176-9. doi: 10.1111/j.1749-6632.2000.tb06366.x. Ann N Y Acad Sci. 2000. PMID: 10818505 Review. - [Apolipoprotein E4 and late-onset Alzheimer's disease].
Tamaoka A. Tamaoka A. Nihon Rinsho. 1994 Dec;52(12):3257-65. Nihon Rinsho. 1994. PMID: 7853720 Review. Japanese.
Cited by
- Opposing Effects of ApoE2 and ApoE4 on Glycolytic Metabolism in Neuronal Aging Supports a Warburg Neuroprotective Cascade against Alzheimer's Disease.
Zhang X, Wu L, Swerdlow RH, Zhao L. Zhang X, et al. Cells. 2023 Jan 25;12(3):410. doi: 10.3390/cells12030410. Cells. 2023. PMID: 36766752 Free PMC article. - Apolipoprotein E Genotype e2: Neuroprotection and Its Limits.
Kim H, Devanand DP, Carlson S, Goldberg TE. Kim H, et al. Front Aging Neurosci. 2022 Jul 14;14:919712. doi: 10.3389/fnagi.2022.919712. eCollection 2022. Front Aging Neurosci. 2022. PMID: 35912085 Free PMC article. Review. - Are apolipoprotein E fragments a promising new therapeutic target for Alzheimer's disease?
Vecchio FL, Bisceglia P, Imbimbo BP, Lozupone M, Latino RR, Resta E, Leone M, Solfrizzi V, Greco A, Daniele A, Watling M, Panza F, Seripa D. Vecchio FL, et al. Ther Adv Chronic Dis. 2022 Mar 17;13:20406223221081605. doi: 10.1177/20406223221081605. eCollection 2022. Ther Adv Chronic Dis. 2022. PMID: 35321401 Free PMC article. Review. - Glycolytic Metabolism, Brain Resilience, and Alzheimer's Disease.
Zhang X, Alshakhshir N, Zhao L. Zhang X, et al. Front Neurosci. 2021 Apr 28;15:662242. doi: 10.3389/fnins.2021.662242. eCollection 2021. Front Neurosci. 2021. PMID: 33994936 Free PMC article. Review. - APOE2 mitigates disease-related phenotypes in an isogenic hiPSC-based model of Alzheimer's disease.
Brookhouser N, Raman S, Frisch C, Srinivasan G, Brafman DA. Brookhouser N, et al. Mol Psychiatry. 2021 Oct;26(10):5715-5732. doi: 10.1038/s41380-021-01076-3. Epub 2021 Apr 9. Mol Psychiatry. 2021. PMID: 33837271 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous